Compare LAB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | RGNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 418.1M |
| IPO Year | 2008 | 2015 |
| Metric | LAB | RGNX |
|---|---|---|
| Price | $0.88 | $8.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $1.35 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.8M | 560.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,937,000.00 | $10,393,000.00 |
| Revenue This Year | N/A | $50.15 |
| Revenue Next Year | $2.63 | $23.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $0.87 | $5.85 |
| 52 Week High | $1.72 | $16.19 |
| Indicator | LAB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 50.69 |
| Support Level | N/A | $8.68 |
| Resistance Level | $1.39 | $9.28 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 10.80 | 69.71 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.